TherapeuticsMD extends debt maturity to Dec 31, 2022; pays $4.2M accrued interest and $750K fee

TherapeuticsMD, Inc.

Amendment No. 17 extends Financing Agreement maturity to Dec 31, 2022, contingent on certain milestones.
Minimum cash covenant set at $7.5M; amendment fee of $750,000 paid to lenders.
Company paid approximately $4.2M in accrued and unpaid interest as of Nov 30, 2022.
Board continues evaluating options to strengthen capital structure and maintain normal operations.
Company faces going-concern risk if it cannot refinance or raise additional capital.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TherapeuticsMD, Inc. amended Amendment No. 17 with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders from time to time party thereto (the “Lenders”) valued at amendment fee in the amount of $750,000 (effective 2022-11-30).

Action: amendment
Agreement: credit facility
Counterparty: Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders from time to time party thereto (the “Lenders”)
Value: amendment fee in the amount of $750,000
Effective: 2022-11-30

Exact text from the filing

On November 30, 2022 (the “Amendment Date”), TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into Amendment No. 17 (“Amendment No. 17”) to that certain Financing Agreement, dated as of April 24, 2019, as amended, with Sixth Street Specialty Lending, Inc., as administrative agent, the various lenders from time to time party thereto (the “Lenders”), and certain of the Company’s subsidiaries party thereto from time to time as guarantors (the “Financing Agreement”).

View on SEC.gov

100 material agreements filed in the last 30 days. Browse all material agreements →

TherapeuticsMD, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-296035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.